开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
据伊朗塔斯尼姆通讯社报道,尽管部分媒体称哈尔克岛发生火灾,但卫星图像分析显示,观测到的热信号升高并非源于美国袭击,而是该岛石油设施常规、计划内的火炬燃烧气体所致,与2026年1月初相比并无变化。因此,关于哈尔克岛石油基础设施遭袭的猜测未得到证实。
2026-07-13
据伊朗塔斯尼姆通讯社报道,尽管部分媒体称哈尔克岛发生火灾,但卫星图像分析显示,观测到的热信号升高并非源于美国袭击,而是该岛石油设施常规、计划内的火炬燃烧气体所致,与2026年1月初相比并无变化。因此,关于哈尔克岛石油基础设施遭袭的猜测未得到证实。
返回
其他消息
2026-07-13
Orient Securities' insurance report says long-dated bonds remain the core of insurers' asset portfolios as allocation shifts from pure duration extension to structural optimization. Persistently low rates are compressing coupon and reinvestment returns; lengthening duration only delays a downward shift in the yield center. The report expects most listed insurers' net investment yields to decline YoY in 2025 as high-coupon stock matures and new allocations earn lower interest. Static estimates sh
Orient Securities' insurance report says long-dated bonds remain the core of insurers' asset portfolios as allocation shifts from pure duration extension to structural optimization. Persistently low rates are compressing coupon and reinvestment returns; lengthening duration only delays a downward shift in the yield center. The report expects most listed insurers' net investment yields to decline YoY in 2025 as high-coupon stock matures and new allocations earn lower interest. Static estimates show long-duration holdings cut annual reallocation needs but cannot fully offset low-rate pressure. Currently 30-year government and local-government bond yields remain above insurers' marginal new liability funding costs, leaving long-duration assets with coupon coverage and duration-matching value; the 30Y-10Y spread has widened markedly from 2025 lows. Insurers' allocation logic is moving to duration matching + term-premium capture + timing-driven positioning.
2026-07-13
China's State Council issued the National Health 15th Five-Year Plan, committing full-chain support for innovative drugs and medical devices. It directs regulators to optimize review and approval of innovative and clinically urgent medicines and to establish a comprehensive clinical evaluation system to support clinical use. The plan calls for accelerated R&D and application of cell and gene therapies, next‑generation antibodies, new vaccines, nucleic‑acid drugs and radiopharmaceuticals, and for
China's State Council issued the National Health 15th Five-Year Plan, committing full-chain support for innovative drugs and medical devices. It directs regulators to optimize review and approval of innovative and clinically urgent medicines and to establish a comprehensive clinical evaluation system to support clinical use. The plan calls for accelerated R&D and application of cell and gene therapies, next‑generation antibodies, new vaccines, nucleic‑acid drugs and radiopharmaceuticals, and for strengthened emergency vaccine and drug R&D, production and deployment. It seeks to expand pediatric drug options, deepen medtech–clinical collaboration and boost R&D of core technologies, components and finished high‑end devices. The plan also promotes AI across the pharma and medtech value chain and instructs improvement of health‑insurance support mechanisms, including refinement of the innovative‑drug reimbursement/catalogue.
Chat with us
, powered by
LiveChat